Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)
China flag China · Delayed Price · Currency is CNY
54.20
-0.64 (-1.17%)
Nov 13, 2026, 3:00 PM CST

SHA:688621 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
473462.17565.56690.93608.93490.25
Short-Term Investments
-8020---
Trading Asset Securities
6075303013.11157.6
Cash & Short-Term Investments
533617.17615.56720.93622.04647.85
Cash Growth
-24.55%0.26%-14.62%15.90%-3.98%492.70%
Accounts Receivable
940.74935.3774.96555.83362.73239.2
Other Receivables
7.386.6510.1611.2116.1712
Receivables
948.13941.95785.12567.04378.9251.21
Inventory
13.9514.0315.0514.4112.547.84
Prepaid Expenses
-----1.9
Other Current Assets
211.44167.4798.7654.7626.4832.99
Total Current Assets
1,7071,7411,5141,3571,040941.79
Property, Plant & Equipment
159.86177.91211.61220.26197.02161.05
Long-Term Investments
237.76179.29115.69100.7594.7540
Goodwill
21.5420.5126.0626.0626.0626.06
Other Intangible Assets
4.254.735.415.394.23.32
Long-Term Deferred Tax Assets
139.84102.2764.0438.9316.695.03
Long-Term Deferred Charges
26.6830.6448.2864.1976.2533.41
Other Long-Term Assets
22.7528.821.7350.318.7831.99
Total Assets
2,3192,2851,9871,8631,4641,243

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
75.449.0930.6849.1222.1312.52
Accrued Expenses
23.0342.0253.6347.4437.2927.33
Short-Term Debt
623.01499.13309.39383.93201.17138.01
Current Portion of Long-Term Debt
32.5219.219.3---
Current Portion of Leases
-17.6324.7822.122.5418.98
Current Income Taxes Payable
14.6931.146.624.9216.9311.42
Current Unearned Revenue
243.18299.15321.43220.83205.85199.85
Other Current Liabilities
10.1911.2812.7612.8812.279.72
Total Current Liabilities
1,022968.65778.56761.21518.19417.83
Long-Term Debt
28.84867.2---
Long-Term Leases
28.429.7535.1240.6233.8449.72
Long-Term Unearned Revenue
4.533.572.523.592.835.46
Long-Term Deferred Tax Liabilities
0.080.051.250.350.24-
Other Long-Term Liabilities
-1.28----
Total Liabilities
1,0841,051884.65805.76555.1473.01

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
1121121121128080
Additional Paid-In Capital
428.49406.54375.86474.17499.85499.85
Retained Earnings
743.85798.83612.78453.85317.09182.1
Treasury Stock
-62.06-100----
Total Common Equity
1,2221,2171,1011,040896.93761.95
Minority Interest
13.0816.122.0117.2511.677.69
Shareholders' Equity
1,2351,2331,1031,057908.6769.64
Total Liabilities & Equity
2,3192,2851,9871,8631,4641,243

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
712.72613.71455.79446.65257.55206.71
Net Cash (Debt)
-179.723.45159.77274.28364.48441.14
Net Cash Growth
--97.84%-41.75%-24.75%-17.38%414.12%
Net Cash Per Share
-1.620.031.422.453.264.50
Filing Date Shares Outstanding
112.45109.28112112112112
Total Common Shares Outstanding
112.45109.28112112112112
Working Capital
684.5771.97735.93595.93521.77523.96
Book Value Per Share
10.8711.149.839.298.016.80
Tangible Book Value
1,1971,1921,0691,009866.68732.57
Tangible Book Value Per Share
10.6410.919.559.017.746.54
Machinery
-261.43256.34232.62195.9124.14
Construction In Progress
-----3.4